The present invention relates to a new polymorph of Rifaximin, designated &kgr;, and to a process for the preparation thereof. Under certain aspects, the invention also relates to pharmaceutical compositions comprising an effective amount of the polymorphic form &kgr; of Rifaximin and a pharmaceutically acceptable carrier and its uses in the treatment of gastrointestinal conditions.